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WMM3
MODELING SEQUENTIAL DECISION-MAKING 
IN PHARMACOECONOMICS
Bala MV1, Zarkin GA2
1Centocor, Inc., Malvern, PA, USA; 2Research Triangle 
Institute, Research Triangle Park, NC, USA
WORKSHOP OBJECTIVE: The objective of this work-
shop will be to develop skills in modeling and analyzing
sequential decision-making problems in pharmacoeco-
nomics.
PARTICIPANTS WHO WOULD BENEFIT: Analysts or
decision-makers involved in the conduct or evaluation of
pharmacoeconomic studies.
Most decision problems in pharmacoeconomics involve
sequential decision-making, where the initial decision is
followed by outcomes that affect subsequent decisions.
However, future decisions are rarely explicitly modeled
in most pharmacoeconomic studies. In this workshop we
examine the problems associated with modeling future
decisions as chance events, and describe the advantages
of explicitly incorporating these future decisions in the
decision model. We start by examining the different
classes of decision problems, including decision-making
under certainty, uncertainty, and risk. We describe how
decision trees are an ideal framework for representing se-
quential decision-making problems. We then use an ex-
ample to illustrate how modeling future decisions as
chance nodes can lead to suboptimal decisions. We also
use the example to illustrate how failure to explicitly
model future decisions can lead to erroneous results dur-
ing sensitivity analysis. We describe how models that ex-
plicitly incorporate future decisions can be used to de-
velop optimal treatment pathways. Further, we argue
that we cannot optimize the initial treatment decision
without identifying the optimal treatment pathway. We
explore possible reasons why future decisions are often
represented as chance nodes in pharmacoeconomic mod-
els. Finally, we extend the discussion to Markov models.
We show how future decisions can be modeled through
the use of Markov decision models, which identify the
optimal treatment strategy for each health state. We will
conclude the workshop with an interactive discussion of
the benefits and drawbacks of explicitly modeling future
decisions in pharmacoeconomic models.
WMS3
SOFTWARE FOR COST-EFFECTIVENESS 
STATISTICAL INFERENCE
Obenchain R
Lilly Research Laboratories, Indianapolis, IN, USA
WORKSHOP OBJECTIVE: This workshop will demon-
strate use of free Microsoft Windows software for calcu-
lation and graphical display of Confidence Regions for
Incremental Cost-Effectiveness Ratios (ICERs) using ei-
ther bootstrapping or Fieller’s theorem methodology.
PARTICIPANTS WHO WOULD BENEFIT: Those who
want to learn how to perform cost-effectiveness analyses
and increase their understanding of ICER confidence in-
terval literature will benefit from this workshop.
The workshop will demonstrate application of statistical/
econometric methods that account for uncertainty and
bias in an Incremental Cost-Effectiveness Ratio (ICER)
comparing two treatments. Participants who bring a lap-
top to the workshop will receive a 3.5” IBM disk con-
taining the software being demonstrated; the software
can also be downloaded via the internet from http://
www.math.iupui.edu/indyasa. The workshop will cover
five topics: 1) how to install the software on a personal
computer running Microsoft Windows 95/NT/98; 2)
how to prepare data input files; 3) how to use the soft-
ware’s menu items and dialog boxes; 4) how to interpret
the printed output and graphical displays; 5) how to
choose between alternative ways of reporting results
(graphical display on the cost-effectiveness plane, ICER
slopes, ICER angles, upper and lower confidence limits,
upper and lower tolerance limits, acceptability curves
and quadrant confidence fractions.)
WMS4
STATISTICAL ISSUES IN THE DESIGNING 




Glaxo Wellcome Inc, Research Triangle Park, NC, USA and 
University of North Carolina, School of Pharmacy, Chapel Hill, 
NC, USA
WORKSHOP OBJECTIVE: The purpose of this workshop
is to identify the statistical issues in designing outcome
studies, calculating sample size, planning data analysis, and
interpreting the results. Various alternative methodology
and their benefits and opportunities to improve will be
discussed.
PARTICIPANTS WHO WOULD BENEFIT: Analysts of
cost and effectiveness data and the audience for the liter-
ature of economic evaluations of healthcare measures,
drugs, and devices who want to increase their under-
standing of such literature.
The differences in design between RCTs and pharmaco-
economic studies will be discussed. When we perform
cost-effectiveness comparison, we create cost-effectiveness
ratios and compare them across treatments. If the vari-
ables, costs and effectiveness are normally distributed, it is
very certain that the cost-effectiveness ratio will not be nor-
mally distributed. So we cannot use traditional methods
to compare cost-effectiveness ratios. Therefore calcula-
tion of power, sample size and p-values is only margin-
ally applicable. Next, we also consider modeling for cost-
effectiveness—such as deterministic or stochastic model-
ing, decision analysis, Markov’s processes, longitudinal
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models and cross-sectional models. Appropriateness of
modeling in pharmacoeconomic studies and methods of
reducing bias will be presented. Finally, the importance
of disclosure of database and the actual model used will
be discussed.
WMD2
THE WHAT, HOW, AND WHY OF THE DELPHI
Downs K, Richter A
Research Triangle Institute, Research Triangle Park, NC, USA
WORKSHOP OBJECTIVE: In this workshop we will
discuss the potential uses of traditional and modified Del-
phi panels for gathering information to be used in eco-
nomic modeling, specifically, mapping medical treatment
algorithms and estimating parameters.
PARTICIPANTS WHO WOULD BENEFIT: Anyone
who develops or uses economic models and is interested
in learning more about the value of the Delphi technique.
The Delphi technique is a structured method for eliciting
expert opinions. Traditional Delphi panels consist of iter-
ative, anonymous questionnaires completed by experts.
Modified Delphi panels include a face-to-face meeting of
the participants in addition to one or more question-
naires. Both methods are intended to add structure and
credibility to the process of obtaining expert opinion for
economic modeling. The goal of this process is to obtain
results that are representative and best reflect current
clinical practices. Delphi panels can be used when pri-
mary data and published sources of information are un-
available, to support other data, or to clarify treatment
patterns which may differ from clinical trial protocols. In
this workshop, we will discuss tactics for incorporating
Delphi results in terms of developing and populating eco-
nomic models with appropriate parameter estimates. We
present the advantages and disadvantages of Delphi pan-
els versus consensus panels as well as the strengths and
weaknesses of traditional Delphi panels versus modified
Delphi panels. We also present common pitfalls that
should be avoided when using either method. We will
discuss expert selection, questionnaire development, and
panel moderation to maximize useful responses. We will
base our discussions on recent experiences with both a
traditional Delphi panel and a modified Delphi panel.
WMD3
NEW METHODS OF DATA COLLECTION IN THE 
COMMUNITY-BASED PHYSICIAN SETTING: 
PROCESS AND TECHNOLOGY
Jardina P, Irwin C
Physicians Data Corporation, Atlanta, GA, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to discuss and develop skills in formulating
new methods for clinical data collection in the commu-
nity-based physician setting.
PARTICIPANTS WHO WOULD BENEFIT: Researchers
who are interested in moving beyond administrative data
for longitudinal outcomes studies, but who are constrained
by the complexity, time, and effort of traditional clinical
data collection methods would benefit from this workshop.
Data collection is a critical component of pharmacoeco-
nomic and outcomes studies, and is often a key limiter of
study design and scope. This workshop identifies several
methods of clinical data collection in the community-
based physician setting. This information has broad util-
ity, including support of the conduct of pharmacoeco-
nomics and outcomes research. Because dictation and
transcription are the preferred means of documenting pa-
tient encounters, this workshop focuses on the role of
people, process and technology within that environment.
Will physicians change their behavior to support collec-
tion of data elements needed to conduct studies? What
types of technologies are needed to support discrete data
element capture in a dictation/transcription environment?
What is the evolving role the electronic medical record in
data collection? How are electronic data stores utilized to
cost-effectively validate source data? How can one over-
come the challenges of codifying data elements that are
collected in natural language? What is the role of manual
processes in augmenting automated data collection? The
workshop will present and explore practical strategies for
collecting, managing and reporting clinical information
in the community-based physician environment. Data
collected through September 1998 on 5865 coronary ar-
tery disease patients will be presented to demonstrate re-
sults from the techniques presented.
WMQ2
A GUIDE FOR SELECTING HEALTH OUTCOMES 
AND QUALITY OF LIFE MEASURES
Erickson P
The On-Line Guide to Quality-of-Life Assessment (OLGA), and 
Department of Health Evaluation Sciences, Hershey Medical 
Center, Penn State University, State College, PA, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop is to develop skills for evaluating alternative mea-
surement strategies for assessing health outcomes and
health-related quality of life in clinical trials and pharma-
coeconomic studies. We will present and discuss the
OLGA model for selecting an instrument or battery of in-
struments that can be used in different types of studies.
This model starts with the identification of the primary
and secondary research questions and includes important
elements in specifying the target population to assure that
the selected measures include the appropriate domains
and subdomains. Important conceptual, methodological
and practical concerns are presented within the context
of the instrument selection model.
PARTICIPANTS WHO WOULD BENEFIT: Pharmaco-
economic and health outcomes researchers who want to
increase their understanding of the issues involved in se-
